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Objectives This study sought to assess the rate of progression of fibrosis by 2 consecutive cardiac magnetic resonance
(CMR) examinations and its relation with clinical variables.
Background In hypertrophic cardiomyopathy (HCM) myocardial fibrosis, detected by late gadolinium enhancement (LGE), is
associated to a progressive ventricular dysfunction and worse prognosis.
Methods A total of 55 HCM patients (37 males; mean age 43  18 years) underwent 2 CMR examinations (CMR-1 and
CMR-2) separated by an interval of 719  410 days. Extent of LGE was measured, and the rate of progression
of LGE (LGE-rate) was calculated as the ratio between the increment of LGE (in grams) and the time (months)
between the CMR examinations.
Results At CMR-1, LGE was detected in 45 subjects, with an extent of 13.3  15.2 g. At CMR-2, 53 (96.4%) patients had
LGE, with an extent of 24.6  27.5 g. In 44 patients, LGE extent increased significantly (1 g). Patients with
apical HCM had higher increments of LGE (p  0.004) and LGE-rate (p  0.001) than those with other patterns
of hypertrophy. The extent of LGE at CMR-1 and the apical pattern of hypertrophy were independent predictors of
the increment of LGE. Patients with worsened New York Heart Association functional class presented higher in-
crease of LGE (p  0.031) and LGE-rate (p  0.05) than those with preserved functional status.
Conclusions Myocardial fibrosis in HCM is a progressive and fast phenomenon. LGE increment, related to a worse clinical sta-
tus, is more extensive in apical hypertrophy than in other patterns. (J Am Coll Cardiol 2012;60:922–9) © 2012
by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.076Clinical presentation of hypertrophic cardiomyopathy
(HCM) is very heterogeneous, varying from asymptomatic
benign forms to malignant arrhythmogenic or severe pro-
gressive expressions, resulting in end-stage HCM (1–3).
Myocardial fibrosis is a pathological hallmark of HCM and
is considered a substrate for ventricular arrhythmias and for
progression to systolic dysfunction (4–7).
Cardiac magnetic resonance (CMR) allows noninvasive
detection and quantification of myocardial fibrosis by late
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2012, accepted March 29, 2012.gadolinium enhancement (LGE) (8). The presence of LGE is
known to be associated with the presence of risk factors for
sudden cardiac death, heart failure symptoms, and evolution to
ventricular dilation and dysfunction (3).
See page 930
Recently a study by O’Hanlon et al. (9) demonstrated the
prognostic role of LGE in HCM as a predictor of the
combined endpoint of cardiovascular death, unplanned cardio-
vascular admission, sustained ventricular tachycardia or ven-
tricular fibrillation, or appropriate implantable cardioverter-
defibrillator (ICD) discharge. Furthermore, Bruder et al. (10)
demonstrated LGE as predictor of cardiac death showing higher
odds ratio than the conventional risk factors for sudden death.
All these studies demonstrated the prognostic role of the
presence of LGE in HCM. However, the rate of progres-
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Objectives of this study were: 1) to assess the amount and
rate of progression of LGE by 2 consecutive CMR exami-
nations; and 2) to evaluate the relationship between the rate
of progression of LGE and clinical variables.
Methods
Population. We enrolled a total of 70 consecutive patients
with a diagnosis of HCM in sinus rhythm without contra-
indications for CMR. All these patients underwent to a first
CMR examination (CMR-1). After CMR-1, 15 patients
were excluded: 2 patients for known significant coronary
artery disease, 8 patients for ICD implantation, 2 patients
for permanent atrial fibrillation (occurred after CMR-1), 1
patient for septal myectomy, and finally 2 patients for
nonsufficient quality of images. The final population that
completed the serial CMR examinations comprised 55
patients. The study was approved by the internal ethical
committee of our institute, and all subjects gave their
written informed consent. We have certified that they
comply with the Principles of Ethical Publishing (11).
All the patients enrolled underwent clinical, electrocar-
diographic, and echocardiographic evaluation at the time of
CMR-1 and CMR-2. The diagnosis of HCM and assess-
ment of the left ventricular (LV) outflow gradient were
based on previously reported echocardiographic criteria
(12). The conventional primary prevention risk markers for
sudden death in HCM were evaluated: family history of
sudden death, extreme LV wall thickness (30 mm),
unexplained (nonvasovagal) syncope, nonsustained ventric-
ular tachycardia on ambulatory electrocardiographic Holter
recordings (4 ventricular beats at a heart rate 120
beats/min), and abnormal “flat” systolic arterial pressure
during exercise stress test (13). A complete clinical evalua-
tion was performed at the enrollment and repeated at
CMR-2. By clinical interrogation, each patient was classi-
fied in a New York Heart Association (NYHA) functional
class on the basis of the presence and the severity of
dyspnea. The history of other symptoms (syncope, chest
pain, palpitation) was also recorded. A 12-lead resting
electrocardiogram was recorded on the day of the CMR
examination. An imaging stress test was performed in all the
patients. When the stress test was positive, evaluation of
coronary anatomy was performed by angiography or coro-
nary computed tomography angiography. Patients with
significant coronary artery disease were excluded from the
study.
CMR protocol. CMR was performed with a dedicated
1.5-T (Signa Hdx, General Electrics Healthcare, Milwau-
kee, Wisconsin) with an 8-channel cardiac phased array coil.
Short-axis cine images from the mitral plane valve to the LV
apex were acquired using a steady-state free precessing
FIESTA (fast imaging employing steady-state acquisition)
pulse sequence with the following parameters: 30 phases,
slice thickness 8 mm, no gap, 8 views per segment, numberof excitation 1, field of view 40
cm, phase field of view 1, 224 
224 matrix, voxel dimensions
1.78  1.78  8 mm, recon-
struction matrix 256  256, 45°
flip angle, repetition time/echo
time equal to 3.5/1.5, and a
bandwidth of 125 KHz. In both
the first and second examinations,
LGE images were acquired 10
min after the administration of
Gd-DTPA (Magnevist, Schering-
AG, Berlin-Wedding, Germany)
with a dosage of 0.2 mmol/kg in
short-axis views. An inversion
recovery T1-weighted gradient
echo sequence was used with the following parameters: field
of view 40 mm, slice thickness 8 mm, no gap between each
slice, repetition time 4.6 ms, echo time 1.3, 20° flip angle,
matrix 224  224, reconstruction matrix 256  256,
number of excitation 1. The appropriate inversion time was
set to null normal myocardium (range 250 to 300 ms) and
it was the same for both CMR examinations.
Image analysis. Analysis of CMR images was performed,
using a commercially available research software package
(Mass 6.1, Leiden, the Netherlands). Left ventricular mass
was measured by the analysis of the cine short-axis images.
The endocardial and epicardial contours of LV myocardium
were manually traced in the end-diastolic and the end-
systolic phases. End-diastolic volume index, end-systolic
volume index, mass, and mass index were measured as
previously described (14,15). Maximal LV end-diastolic
wall thickness was measured as previously described (16).
omparing the 2 CMR examinations, a significant change
n LV mass was defined for a measured difference5 g. The
xtent of LGE was measured using a previously validated
ethod (17). Briefly, endocardial and epicardial contours in
ach image were manually traced to identify LV myocar-
ium in each image. To obtain the standard deviation of the
ignal noise of the images a region of interest was placed in
he background of the image, near the patient’s thoracic
all. The mean signal intensity and standard deviation were
easured in this region of interest.
Myocardial voxels with signal intensity higher than the
verage signal intensity of the region of interest plus 6
tandard deviations were considered enhanced (18,19). The
ercentage of enhanced voxels in the entire LV myocardium
as measured. Extent of LGE was expressed in grams and
ercentage of LV mass. A significant increase of LGE was
efined when the extent of LGE increased of 1 g at
CMR-2. This threshold was chosen because in considering
the dimensions of the voxel, 1 g of LGE was equivalent to
50 voxels. The rate of progression of LGE (LGE-rate)
was defined as the ratio between the increment of LGE
extent in grams and the time (months) between the 2
Abbreviations
and Acronyms
CMR  cardiac magnetic
resonance
HCM  hypertrophic
cardiomyopathy
ICD  implantable
cardioverter-defibrillator
IQR  interquartile range
LGE  late gadolinium
enhancement
LV  left ventricular
NYHA  New York Heart
Associationexaminations. Quantification of LGE was performed in a
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1) the clinical information of the patients; and 2) the value
of LGE extent measured at CMR-1.
Statistical analysis. Categorical variables were compared
y Pearson chi-square test or Fisher exact test as appropri-
te; the McNemar and the Cochran tests were employed for
nalyzing changes in patients’ proportions among classes
e.g., NYHA functional class) between CMR-1 and
MR-2. Statistical tests used to compare groups included
aired/unpaired Student t test for difference in mean values
and Mann-Whitney U test or Wilcoxon test for skewed
ariables. The Wilcoxon signed rank test was employed for
aired measurements while the Wilcoxon rank sum test
Mann-Whitney U test) was used for 2 independent groups.
The Pearson correlation coefficient was employed for
uantifying the relationship between Gaussian distributed
ariables; for skewed variables, the logarithmic transforma-
ion was applied (LGE extent in grams, LGE extent in
ercentage of LV mass, and increment of LGE extent).
imple and multiple linear regression analyses were then
onducted for quantifying the effect of parameters at CMR-1
n relation to LGE changes at CMR-2. The Kolmogorov-
mirnov test was employed to assess normality of data distri-
ution and for the residuals of regression models. A p value
0.05 was considered statistically significant.
Data are presented as mean  SD, median and inter-
uartile range (IQR: 25th to 75th percentile), and as
roportions with percentage, as indicated. Statistical analy-
es were performed using MATLAB (The MathWorks,
atick, Massachusetts).
esults
opulation. The final population of patients with HCM
ho completed the serial CMR examinations included 55
atients. The average interval between CMR-1 and
MR-2 was 719  410 days.
Clinical characteristics of the study population are sum-
arized in Table 1.
Thirty-seven patients were males. Age ranged from 14 to
3 years (mean 42.4  17.7 years).
Of the 55 patients, 35 (63.6%) were in NYHA functional
lass I, 19 (34.5%) in class II, and 1 (1.8%) in class III at the
ime of CMR-1 evaluation. HCM was obstructive in 5
atients (9%). Ten patients had 2 arrhythmic risk factors.
hree patients had a stress imaging test positive for induc-
ble ischemia despite a coronary artery angiography without
ignificant stenosis in the epicardial coronary arteries.
MR-1. Measurements obtained at CMR-1 are summa-
ized in Table 1. At CMR-1, LV mass index was upper the
range of normality in 43 (78.2%) of the study patients. The
mean maximal end-diastolic wall thickness was 20.8  5.4
mm (range 15 to 38 mm) and was 30 mm in 3 patients
(5.5%). Myocardial hypertrophy mainly involved the inter-
ventricular septum and/or the anterior free wall in 32
(58.2%) patients of the study population. Hypertrophy wasconfined in the ventricular apex in 10 patients (18.2%) and
to the inferior and/or inferolateral wall in 3 patients (5.5%).
Finally, hypertrophy was diffuse in 10 patients (18.2%).
Mean LV end-diastolic volume index was 75.5  17.5
ml/m2. Mean LV ejection fraction was 68.9  9.6%, and
was 50% in only 1 patient (ejection fraction  37%).
LGE was detected in 45 (81.8%) of the study patients.
The median of LGE extent was 8 g (IQR: 3 to 18 g) with
a non-Gaussian distribution (p 0.001). On average, LGE
as identified in 2.3 1.9 (range 0 to 6 segments) of the 16
onventional myocardial segments into which the myocar-
ium was subdivided.
MR-2. Measurements obtained at the CMR-2 are sum-
arized in Table 1. LV mass augmented in 30 patients
54.5%), remained substantially unchanged in 21 (38.2%),
nd decreased in 4 patients (7.3%) (Fig. 1). The mean extent
f LGE increased from 13.3  15.2 g at CMR-1 to 24.6 
7.5 g at CMR-2 (p 0.001). LV ejection fraction (average
8.5  9.4%) did not change significantly from CMR-1
p  0.923).
LGE extent increased (1 g) in 44 patients (80%). The
edian LGE increment was 6 g (IQR: 2 to 14 g) (Fig. 2). LGE
xtent was unchanged (difference of LGE extent 1 g) in 6
atients and decreased in 2. Among the 11 patients without
etectable LGE at CMR-1, 8 patients showed ex novo
GE at CMR-2 (Fig. 3). Thus at CMR-2, LGE was
lobally found in 53 (96.4%) patients. In 15 patients
27.3%), the number of myocardial segments with LGE
ignificantly increased from CMR-1 to CMR-2, while in 25
atients (45.5%), the increase of LGE was confined in the
ame segments of CMR-1. LGE-rate was 0.54  0.98
/month (range 0 to 6 g/month).
During the time interval between the CMR examina-
ions, NYHA functional class improved from II to I in 3
atients who started medical therapy after CMR-1, and
orsened in 13 patients (10 from NYHA functional class I
o II, 3 from NYHA functional class II to III). Therefore,
t CMR-2, 23 patients were in NYHA functional class II
nd 4 in NYHA functional class III.
GE increment and clinical correlates. The increment of
GE extent (logarithmic values) between the 2 CMR scans
as inversely related to the age at the enrollment (r 
0.309, p  0.024). The LGE increment was not corre-
ated to the time interval between them (r  0.044, p 
0.758), and no difference was observed between males and
females (p  0.592).
Patients with apical HCM had a higher increment of
LGE (median 11, IQR: 3 to 22 g vs. median 5, IQR: 2 to
11 g; p  0.004) and LGE-rate (1.40  1.78 g/month vs.
0.33  0.53 g/month; p  0.001) than those with other
patterns of hypertrophy, despite a nondissimilar increase in
LV mass (32.0  33.9 g vs. 11.8  31.0 g; p  0.142); in
addition, there was no significant difference in the relation-
ship between LGE at CMR-1 and LGE rate in the 2
groups (interaction term p  0.818). Patients with apical
HCM had also a higher increment of LGE indexed by the
etic re
lar; NYH
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other patterns. Patients with worsening of NYHA func-
tional class had higher increase of LGE extent (median 13,
IQR: 3 to 18 g vs. median 2, IQR: 1 to 8 g; p  0.031) and
higher LGE-rate (1.15  1.57 g/month vs. 0.40  0.51
g/month; p 0.049) than those with preserved or improved
clinical functional status.
A significant direct relationship between the increase of
LV mass index and the increment of LGE was observed
(r 0.504, p 0.001); furthermore, the increment of LGE
was related to the extent of LGE at CMR-1 (r  0.498,
p 0.001). Differently, LGE increase was not related to the
LV mass index at CMR-1 (p  0.352), ejection fraction
(p  0.068), and the maximal end-diastolic wall thickness
(p  0.077).
The apical pattern of hypertrophy and the extent of LGE
at CMR-1 were significant independent predictors of the
Clinical Variables of the Population in CMR-1 anTable 1 Clinical Variables of the Population
Clinical Variables
Patients
Symptoms
Syncope
Angina
Effort dyspnea (NYHA functional class II)
Palpitation
Arrhythmic risk factors
Patients with 0 risk factor
Patients with 1 risk factor
Patients with 2 risk factors
Maximal end-diastolic wall thickness 30
Unexplained syncope
VT at 24-h Holter monitoring
Family history of sudden death
Outflow pulse gradient 30 mm Hg
Abnormal pressure response during effort
Morphofunctional abnormalities
History of paroxysmal atrial fibrillation
Atrial dilation
Reduced ejection fraction (50%)
Mitral regurgitation (mild)
CMR findings
LV mass index, g/m2
Maximal end-diastolic thickness, mm
Ejection fraction, %
End-diastolic volume index, ml/m2
LGE detectable
LGE extent, g
LGE extent (% of LV mass)
Therapy
Beta-blockers
Calcium antagonist
ACE inhibitors
Diuretic
Values are n, n (%), mean  SD, or median (25th to 75th interquartil
ACE  angiotensin-converting enzyme; CMR-1  first cardiac magn
examination; LGE  late gadolinium enhancement; LV  left ventricuincrement of LGE between the examinations, in a multi-variate model containing age as a covariate: the regression
model overall explained almost 35% of the variability of
LGE increase (Table 2). On average, having an apical
pattern of hypertrophy would result in approximately 19-g
increase of LGE and a 10-g LGE extent at CMR-1 would
correspond to an average increase of approximately 4 g at
CMR-2.
Discussion
HCM is an evolutive disease, so it is intuitive to consider
fibrosis a progressive phenomenon, however, the rate of
progression of LGE was not previously evaluated. In this
study we assessed for the first time the rate of progression of
LGE by repeated CMR examinations in HCM patients.
The main results were: 1) after an average of 2 years the
prevalence of LGE increase from 81.8% to 96.4% of
R-2R-1 and CMR-2
R-1 CMR-2 p Value
5 55 —
5) 3 (5) —
22) 12 (22) —
22) 20 (36) 0.11
22) 16 (29) 0.5
51) 27 (50) —
13) 6 (12.5) 0.99
18) 11 (20) 0.99
5) 4 (7) 0.99
5) 3 (5) —
13) 9 (16) 0.8
7) 4 (7) —
9) 6 (12.5) 0.99
1 1 —
9) 7 (13) 0.99
31) 17 (31) 0.99
1 1 —
5) 3 (5) —
 23.1 113.1 26.8 0.036
 5.4 21.7 6.1 0.506
 9.6 68.5 9.4 0.923
 17.5 74.5 16.5 0.075
81.8) 53 (96.4) 0.031
3–8) 17 (6–36) 0.001
2–9) 8 (3–15) 0.001
50) 32 (58) 0.8
9.1) 2 (5) 0.99
5.5) 4 (10) 0.99
1.8) 1 (1.8) —
).
sonance examination; CMR-2  second cardiac magnetic resonance
A  New York Heart Association; VT  ventricular tachycardia.d CMin C
CM
5
3 (
12 (
12 (
12 (
28 (
7 (
10 (
3 (
3 (
7 (
4 (
5 (
5 (
17 (
3 (
109.0
20.8
68.9
75.5
45 (
8 (
4 (
27 (
5 (
3 (
1 (
e rangesubjects and the extent of LGE increased in the majority of
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of LGE and higher LGE-rate than those presenting
other patterns of hypertrophy; and 3) the increment of
LGE was higher in patients with worsening NYHA
functional class.
The presence of LGE in patients with HCM may be
considered relevant in terms of prognostic stratification, as
recent reports demonstrated that after a clinical follow-up of
3 years, patients with LGE had worse prognoses than those
without LGE (9,10). However, the specificity of LGE as
prognostic marker in HCM should be rediscussed because it
is detected in most of the patients at the first evaluation and
in almost all of them after few years, as shown by these
results. Then, the clinical and prognostic role of other
Figure 1 LV Mass Index at CMR-1 and CMR-2 in the Different
Left ventricular (LV) mass index was not significantly higher in patients with apical
of hypertrophy at CMR-1 (left) and CMR-2 (right). CMR-1  first cardiac magnetic
Figure 2 Apical Hypertrophic Cardiomyopathy at CMR
Late gadolinium enhancement (LGE) images of a patient with apical HCM at CMR-
Short- and long-axis images clearly show that the extent of LGE increased significafeatures of LGE as its global extent, the pattern of distri-
bution and the rate of progression should be evaluated by
further studies in HCM patients.
In this study we evaluated the increment of LGE between
2 CMR examinations performed in a time range of 719 
410 days and calculated a new index, the LGE-rate, defined
as the ratio between the increment of LGE in grams and the
time in months between the 2 CMR examinations, which
represents the rate of progression of LGE over time.
LGE-rate was used to compare the progression of LGE
extent in patients with a different time gap between the
CMR examinations. However, results showed that the
increment of LGE was not related to the time interval
between the 2 CMR examinations, and the rate of progres-
rns of Hypertrophic Cardiomyopathy
trophic cardiomyopathy than in those with other patterns
ance examination; CMR-2  second cardiac magnetic resonance examination.
) and CMR-2 (right).
bbreviations as in Figure 1.Patte
hyper
reson1 (left
ntly. A
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September 4, 2012:922–9 Myocardial Fibrosis in Hypertrophic Cardiomyopathysion of LGE was highly heterogeneous with a spectrum of
values of LGE-rate ranging from 0.06 to 2.53 g/month.
Although at CMR-1 the extent of LGE was not different
in patients with different patterns of hypertrophy (Fig. 4),
patients with apical HCM had higher increment of LGE
and higher LGE-rate than other patterns of HCM at
CMR-2 (Fig. 5). Moreover, at multiple regression analysis
the apical pattern together with the extent of LGE at the
first examination were independent predictors of the incre-
ment of LGE extent. In a case report, Gebker et al. (20)
described a large increment of LGE extent in patients with
apical HCM between 2 CMR examinations after a time
interval of 2 years. Several mechanisms may account for the
higher progression of fibrosis in the apical pattern of LV
Figure 3 Diffuse Hypertrophy at CMR
LGE images of a patient with diffuse hypertrophy at CMR-1 (left) and CMR-2 (right
at CMR-2 LGE was detected in the anterior and lateral wall. Abbreviations as in Fig
Multiple Regression Model for the Prediction of Increment of LGE ETable 2 Multiple Regression Model for the Prediction of Increm
Predictors Mean Beta Coefficient (95% Confidence I
Age, yrs 0.172 (0.419 to 0.075)
Extent of LGE at CMR-1, g 0.354 (0.072 to 0.636)
Apical pattern of HCM 18.63 (7.53 to 29.73)
Constant, g 10.47 (2.42 to 23.36)Bold values indicate independent predictors of LGE extent at CMR-2.
CMR-1  first cardiac magnetic resonance examination; CMR-2  second cardiac magnetic resonancehypertrophy. The physiological rarefaction of capillary den-
sity at the ventricular apex may contribute to the mismatch
between oxygen demand and supply in hypertrophic apical
segments. In fact, Moon et al. (21) demonstrated perfusion
defect at the hypertrophied segment, representing abnormal
myocardial capillary density, in apical HCM patients (22).
In patients with apical HCM the development of apical
aneurysm may be the extreme consequence of the increased
fibrosis, shrinkage, and severe wall thinning (21,23). Yet,
myocardial infarction appears to be a common complication
of apical HCM during long-term follow-up, even without
significant coronary artery disease (24,25). Finally, a genetic
predisposition may condition the rate of progression of
fibrosis in apical as well in other patterns of HCM.
he first examination LGE was not detected,
and 2.
t at CMR-2f LGE Extent at CMR-2
Total R2  0.348, p < 0.001
l) Standardized Beta p Value Partial R2
0.168 0.168 2.6%
0.296 0.015 8.5%
0.400 0.001 15.1%
— 0.109 —). At t
ures 1xtenent o
ntervaexamination; HCM  hypertrophic cardiomyopathy; LGE  late gadolinium enhancement.
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Myocardial Fibrosis in Hypertrophic Cardiomyopathy September 4, 2012:922–9On the clinical point of view, a significant correlation
between LGE and impaired functional class (NYHA func-
tional class II) was already demonstrated in previous
eports (26,27). In addition, the current study showed a
elation between the rate of progression of fibrosis and the
linical status: patients with worsened NYHA functional
lass had a higher increment of LGE and LGE-rate than
hose with unchanged functional status. This result may be
xplained by the previous observation that impaired diastolic
unction was related to the extent of LGE in HCM (26)
nd, consequently, a positive relation between the LGE-rate
nd the worsening of diastolic function may be hypothe-
ized to justify the association between worsened NYHA
nd LGE-rate.
tudy limitations. The main limitation of this study was
he small size of the population. This was expected, con-
Figure 4 LGE in Different Patterns of Hypertrophic Cardiomyop
The histograms show the extent of LGE in the different patterns of hypertrophic ca
patients with apical hypertrophy had higher extent of LGE at CMR-2. Abbreviations
Figure 5 Increments of LGE
Box and whisker plot showing that the increment of LGE were significantly (*)
higher in patients with apical pattern than those with diffuse hypertrophy or
septal-anterior hypertrophy.sidering the percentage of HCM patients undergoing to
ICD implantation after the first CMR and those with atrial
fibrillation not permitting the acquisition of CMR images
because of a nonoptimal electrocardiogram triggering.
Another limitation was that the coronary artery angiog-
raphy was performed only in patients with a positive exercise
stress test. However, 36 patients with a negative stress test
were 45 years of age and 17 of them were 30 years of
age. The Framingham Risk score demonstrated a 10%
isk for coronary artery disease in all the remaining 16
atients (28). Furthermore, the pattern of distribution of
GE in all the patients in the 2 CMR examinations was not
schemic-like; it was intramural, patchy, and nonrespecting
f the coronary vessel territory (29). Yet, in this study,
enetic analysis for the screening of sarcomeric mutations
as not performed, and further investigations are needed to
ssess whether the rate of progression of fibrosis may be
onditioned by a genetic predisposition.
onclusions
he progression of fibrosis in HCM is very fast, though very
eterogeneous, and is faster in apical hypertrophy than in
ther patterns and it is related to the worsening of the
linical status. Therefore CMR can be applied as a useful
nd safe tool for longitudinal follow-up evaluation of HCM.
owever, the clinical and prognostic impact of the LGE-
ate, evaluated by repeated CMR examinations, needs to be
ssessed by further studies, assessing also whether multiple
MR examinations over time could be more useful than a
single shot” approach in the clinical setting.
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